* The listed price of $30.00 for cultures and plasmids is for academic and non-profit users. Commercial and industrial users are charged $300.00 for each strain or plasmid and twice the listed price for media components. BACs and fosmids are $50.00 for academic and non-profit users and $500 for commercial/industry. For the Jonikas CLiP mutants, the price is $100.00 each for academic and non-profit users and commercial and industrial users are charged $500.00.

CC-5665 ift81-1 IFT81(2E) mt+

Name: CC-5665 ift81-1 IFT81(2E) mt+
SKU: CC-5665
Availability: InStock

$30.00

From George B. Witman, University of Massachusetts Medical School, August 2020

This strain expresses IFT81(2E) in a background null for IFT81. IFT81(2E) is a version of IFT81 in which two highly conserved basic residues (K73 and R75) in the proteinâ€™s calponin-homology domain, implicated in binding to tubulin, have been replaced by glutamate. The strain has apparently normal length flagella, normal flagellar regeneration kinetics, normal motility, and normal IFT. The frequency of anterograde tubulin IFT was not significantly reduced in the flagella of this strain.

It was created by insertional mutagenesis of the parent strain with a fragment conferring resistance to hygromycin B (aph7â€) to generate ift81-1, followed by transformation with a DNA fragment encoding IFT81(2E) and containing a paromomycin-resistance gene as a selectable marker.

Mutant allele: ift81-1, chromosome_17:3362408-3368081

Kubo T, Brown JM, Bellve K, Craige B, Craft JM, Fogarty K, Lechtreck KF, Witman GB. Together, the IFT81 and IFT74 N-termini form the main module for intraflagellar transport of tubulin. J Cell Sci. 2016 May 15;129(10):2106-19. doi: 10.1242/jcs.187120. Epub 2016 Apr 11. PMID: 27068536; PMCID: PMC5506485.

Locus:
IFT81
Chromosome:
17
Mutation Information:
Predicted Mutation Effect:

CC-5665 ift81-1 IFT81(2E) mt+

Products

Support

Banner Photo Credit: Chlamydomonas reinhardtii zygotes were stained for immunofluorescence with anti-acetylated tubulin (green), anti-phospholipase D (red), and DAPI (blue) by Karl F. Lechtreck (University of Georgia) and George B. Witman (University of Massachusetts Medical School).

Any opinions, findings, and conclusions or recommendations expressed on this website are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.

Cart